Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 831-842

  Johnston, Thomas P ^a   Baker, Jacqueline C ^a   Jamal, Ahmed S ^a   Hall, Douglas ^a   Emeson, Eugene E ^b   Palmer, Warren K ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Atherosclerosis; HMG CoA reductase; Hyperlipidemia; Lipoprotein lipase; Poloxamer 407

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; POLOXAMER;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HYPERLIPIDEMIA; LIPID METABOLISM; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ARTERIOSCLEROSIS; BODY WEIGHT; CHOLESTEROL; DIET; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATITIS, TOXIC; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEIN LIPASE; LIVER; MICE; MICE, INBRED C57BL; POLOXAMER; RNA, MESSENGER; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES;

EID: 0032734530     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00010     Document Type: Article

References (47)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 1987;257: 2176-80.
2. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel in detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
3. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
4. Farnier JA, Washington LC, Jones PH, Shapiro DR, Gotto AM, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 1992;14:708-17.
5. Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Israel J Med Sci 1993;29:272-7.
6. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-24.
7. Palmer WK, Emeson EE, Johnston TP. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998;136: 115-23.
8. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993;46: 1037-12.
9. Wout Z, Pec EA, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injections to rats. J Parenter Sci Technol 1992;46:192-200.
10. Porter J, Carter BL, Johnston TP, Palmer WK. Effect of pravastatin on poloxamer 407-induced hyperlipidemia in rats. Pharmacotherapy 1995;15:92-8.
11. Johnston TP, Palmer WK. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 1997; 17:342-7.
12. Johnston TP, Palmer WK. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J Cardiovasc Pharmacol 1997;29:580-5.
13. Nash VL, Johnston TP, Palmer WK. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy 1996; 16:10-5.
14. Palmer WK, Emeson EE, Johnston TP. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exerc 1997;29:1416-21.
15. Schmolka IR. Poloxamers in the pharmaceutical industry. In: Tarch PJ, ed. Polymers for controlled drug delivery. Boca Raton: CRC Press, 1991:189-215.
16. Paigen B, Plump AS, Rubin EM. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol 1994;5:258-64.
17. Jokinen M, Clarkson T, Prichard R. Animal models in atherosclerosis research. Exp Mol Pathol 1985;42:1-28.
18. Ishida BY, Paigen B. Atherosclerosis in the mouse. In: Lusis AJ, Sparkes SR, eds. Genetic factors in atherosclerosis: approaches and model systems: monographs in human genetics. Basel: Karger, 1989:189-222.
19. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990;10:316-23.
20. Edwards PA, Lemongello D, Fogelman AM. Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 1979;20:40-6.
21. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-9.
22. Allain CA, Poor LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20: 470-6.
23. Bachorik PS, Albers JJ. Precipitation methods for quantitation of lipoproteins. Methods Enzymol 1986;129:78-100.
24. Purcell-Huynh DA, Farese RV, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995;95:2246-57.
25. Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57BL/5 mice treated with cyclosporin A. Am J Pathol 1993; 142:1906-15.
26. Larrick JW. Message amplification phenotyping (MAPPing) - principles, practice, and potential. Trends Biotechnol 1992;10: 146-52.
27. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
28. Sambrook J, Fritsch EF, Maniatis T. In: Sambrook J, Fritsch EF, Maniatis T, eds. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989:1-137.
29. Snedecor GW, Cochran WG. One-way classifications; analysis of variance. In: Snedecor GW, Cochran WG, eds. Statistical methods. Ames: Iowa State University Press, 1980:215-33.
30. Hwa JJ, Zollman S, Warden CH, et al. Genetic and dietary interactions in the regulation of HMG-CoA reductase gene expression. J Lipid Res 1992;33:711-25.
31. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993;132:2246-53.
32. Shefer S, Nguyen LB, Salen G, et al. Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7α-hydroxylase activities and mRNA levels in the rat. J Lipid Res 1992;33:1193-200.
33. Dueland SA, Lusis AJ, Machlader D, Davis RA. Altered regulation of HMG-CoA reductase and cholesterol 7α-hydroxylase in mice. Arteriosclerosis 1990;10:785a.
34. Breslow JL. Mouse models of atherogenesis. Science 1996;272: 685-8.
35. Witztum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:875-99.
36. Nordestgaard BG, Zilversmit DB. Hyperglycemia in normotriglyceridemic, hypercholesterolemic insulin-treated diabetic rabbits does not accelerate atherogenesis. Atherosclerosis 1988;72:37-47.
37. Van Heek M, Zilversmit DB. Evidence for an inverse relation between plasma triglyceride and aortic cholesterol in the coconut oil/cholesterol-fed rabbit. Atherosclerosis 1988;71:185-92.
38. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res 1988;29:1491-500.
39. Nordestgaard BG, Stender S, Kjeldsen K. Severe hypertriglyceridemia, large lipoproteins and protection against atherosclerosis. Scand J Clin Lab Invest 1987;47(suppl 186):7-12.
40. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits: giant lipoproteins do not enter the arterial wall. Arteriosclerosis 1988;8:421-8.
41. Minnich A, Zilversmit DB. Impaired triacylglycerol catabolism in hypertriglyceridemia of the diabetic, cholesterol-fed rabbit: a possible mechanism for protection from atherosclerosis. Biochim Biophys Acta 1989;1002:324-32.
42. Duff GL, McMillan GC. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit: I. the inhibition of experimental cholesterol atherosclerosis in alloxan diabetes: II. the effect of alloxan diabetes on the retrogression of experimental cholesterol atherosclerosis. J Exp Med 1949;89:611-30.
43. Duff GL, Payne TPB. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit: III. the mechanism of the inhibition of experimental cholesterol atherosclerosis in alloxan-diabetic rabbits. J Exp Med 1950;92:299-317.
44. Pierce FT Jr. The relationship of serum lipoproteins to atherosclerosis in the cholesterol-fed alloxanized rabbit. Circulation 1952;5: 401-7.
45. Brecher AP, Chobanian AV, Small DM, et al. Relationship of an abnormal plasma lipoprotein to protection from atherosclerosis in the cholesterol-fed diabetic rabbit. J Clin Invest 1983;72:1553-62.
46. Miller RA, Wilson RB. Atherosclerosis and myocardial ischemic lesions in alloxan-diabetic rabbits fed a low cholesterol diet. Arteriosclerosis 1984;4:586-91.
47. Van Sickle WA, Brecher AP, Aspen A, Chobanian AV. Effect of fasting on the composition of plasma lipoproteins in cholesterol-fed diabetic rabbits. J Lipid Res 1985;26:442-50.